Joseph (Joe) Beaulieu is a financial and operational leader with over 20 years of finance and accounting experience in the life sciences space and public accounting. He most recently served as Senior Vice President, Head of Finance for Epizyme, Inc., which was acquired by Ipsen in August 2022. In this role, he supported the commercial launch of Tazverik® (tazemetostat) for the treatment of relapsed or refractory follicular lymphoma and was responsible for capital funding, treasury, tax and accounting. During his tenure he helped raise over $450 million across multiple equity and debt financings. Joe began his career in public accounting at Ernst & Young LLP where he held positions of increasing responsibility for a combined 14 years. A Certified Public Accountant, Joe holds a BS degree in Business Administration with dual concentrations in Accounting and Management Information Systems from Boston College’s Wallace E. Carrol School of Management.
by